Company Overview
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Company Information
- CEO
- John F. Sheridan
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 2650
Contact Information
- Address
- 11075 Roselle Street
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 721.64M market capitalization
- Trading Volume: 2.74M shares traded today
- Price Range: 52-week range of $9.98 - $47.60
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (TNDM) operates in the Medical - Devices industry within the Healthcare sector. With a current market capitalization of 721.64M, the company represents a significant player in its market. The stock is currently trading at $10.68 with a negativedaily change of 1.93%.
The company's 2650 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -3.47, beta of 1.47, and 52-week price range from $9.98 to $47.60when evaluating investment opportunities.
Why Invest in Tandem Diabetes Care, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under John F. Sheridan
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.